GlassScriptPhysician profile
Thomas P Blodgett
NPI 1619059516
$3,072.45
in general payments reported to CMS, 2019-2025
19 companies · $99.20 in 2025
The $99.20 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $386 · 2021: $412 · 2022: $629 · 2023: $861 · 2024: $132 · 2025: $99.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.66 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,294.76 | 2019-2025 | Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $574.89 | 2019-2024 | |
| Janssen Biotech, INC. | $293.28 | 2021-2023 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $217.00 | 2022-2024 | |
| Lilly USA, LLC | $214.49 | 2021-2023 | Taltz |
| Merck Sharp & Dohme LLC | $108.12 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $102.73 | 2019-2024 | Siliq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.37 | 2023-2024 | Cyltezo, Spevigo |
| Regeneron Healthcare Solutions, INC. | $32.49 | 2019-2021 | |
| Ucb, INC. | $29.96 | 2019 | |
| Incyte Corporation | $29.42 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $23.35 | 2023 | Adbry |
| Prugen, INC. Pharmaceuticals | $22.51 | 2019-2020 | |
| Biofrontera INC. | $20.67 | 2019 | |
| Amgen INC. | $16.06 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $13.83 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $12.59 | 2022 | |
| Glaxosmithkline, LLC. | $12.01 | 2019 | |
| Mission Pharmacal Company | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Blodgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.